Envarsus XR Compared to Immediate Release Tacrolimus

  • STATUS
    Recruiting
  • End date
    Jun 1, 2022
  • participants needed
    240
  • sponsor
    Mayo Clinic
Updated on 26 January 2021

Summary

The purpose of this study is to compare once-daily tacrolimus extended-release (Envarsus XR) to twice-daily immediate release tacrolimus to find out if people taking tacrolimus extended release (Envarsus XR) report fewer side effects, increased medication compliance and higher scores on quality of life assessments compared to people taking twice daily tacrolimus immediate release.

Description

Despite improvement in short-term graft outcomes in organ transplant, transplant patients still have to take on complex medication regimens to achieve current results. Adherence to these complex medications is an important problem in light of the potential risk of acute and chronic rejection and the associated burden of increased hospitalization, cost, and diminished quality of life that results from missed doses and poor overall drug taking. Part of the diminished quality of life is also tied to the bothersome symptoms patient feel after transplant. Most patients experience symptoms that relate to either the overall transplant immunosuppression or medication specific side effects. In the BENEFIT and BENEFIT-EXT trials, >60% of patients reported tiredness and lack of energy as an issue. Sleep problems, mood swings, restlessness, anxiety, depression, and concentration and memory difficulties appeared in approximately 50-60% of patients. In addition to these symptoms, >38% patients also reported numerous others side effects that have been strongly associated with calcineurin-inhibitors such as tacrolimus that include dizziness, muscle cramps, trembling hands, tingling in hands and feet, and headache.

The investigators hypothesize that the use of once-daily Envarsus XR could decrease some transplant- and tacrolimus-related adverse symptoms and potentially lead to improvement in quality of life and medication adherence when compared to twice-daily tacrolimus. In order to assess this hypothesis, a prospective, multi-center, randomized, open-label, pilot study to investigate medication adherence and patient reported symptom occurrence and interference with daily life comparing once-daily Envarsus XR and twice-daily immediate release tacrolimus in adult renal transplant recipients (SIMPLE) is being proposed.

Details
Condition Kidney Transplant Recipients
Treatment Envarsus XR, Tacrolimus twice daily
Clinical Study IdentifierNCT03979365
SponsorMayo Clinic
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Gender: Male or Female
Do you have Kidney Transplant Recipients?
Do you have any of these conditions: Do you have Kidney Transplant Recipients??
Do you have any of these conditions: Do you have Kidney Transplant Recipients??
Do you have any of these conditions: Do you have Kidney Transplant Recipients??
Patient is an adult (18 years of age or older)
Patient is a recipient of a deceased or living donor kidney transplant
Patient is able to comply with study procedures for the entire length of the study
Patient has been informed about the study survey and has signed an informed consent form

Exclusion Criteria

Patient is unable or unwilling to complete study patient reported outcome questionnaires
Patient is currently receiving azathioprine
Patient is currently receiving an mTOR inhibitor (sirolimus, everolimus)
Patient is currently receiving an belatacept
Patient has received investigational immunosuppression 1 month prior to transplant or post-transplant
Patient is in a setting where a professional care taker is responsible for dispensing subject's medication
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note